V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320006609 | 320005820 | null | 63.65 | Palliative (P) | 2018-07-18 | 2018-08-03 | Temozolomide 150mg/m2 | N | N | 320023216 | GEMCITABINE |
| 320006610 | 320003975 | null | 55.7 | Palliative (P) | 2019-04-05 | 2019-04-05 | Trabectedin | 02 | N | 320023226 | CYCLOPHOSPHAMIDE + VINORELBINE |
| 320006611 | 320003975 | null | 40.4 | Palliative (P) | 2015-05-27 | 2015-06-03 | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | 2 | N | 320023226 | BCG |
| 320006612 | 320003977 | 1.83 | 68.7 | Curative (C) | 2016-03-28 | 2016-06-25 | IBRUTINIB | N | N | 320023253 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 320006613 | 320003978 | 1.7 | 67.8 | Palliative (P) | 2019-12-26 | 2020-01-01 | Ipilimumab | 02 | N | 320023270 | LANREOTIDE |
| 320006614 | 320005824 | 1.48 | 68 | Palliative (P) | 2016-07-19 | 2016-07-19 | FLUOROURACIL + OXALIPLATIN | N | N | 320023276 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320006615 | 320003982 | 1.81 | 66.1 | Not known (9) | 2017-09-18 | 2017-12-09 | Bevacizumab + CAPECITABINE + OXALIPLATIN | null | null | 320023297 | TEMOZOLOMIDE |
| 320006616 | 320003984 | null | 58.7 | Adjuvant (A) | 2015-04-27 | 2015-05-01 | BEVACIZUMAB + CARBO | 02 | N | 320023313 | DOCETAXEL |
| 320006617 | 320003985 | 1.51 | 47.3 | Palliative (P) | 2013-08-26 | 2014-03-06 | Doxorubicin + Olaratumab | N | N | 320023333 | RMS 2005 TRIAL |
| 320006618 | 320003986 | null | 64.4 | Disease modification (D) | 2014-04-12 | 2014-05-14 | VAI (Ifos 3g/m2) | N | N | 320023358 | ICON8B TRIAL |
| 320006619 | 320003987 | 1.51 | 65.2 | Adjuvant (A) | 2014-08-28 | 2014-12-09 | Vinorelbine (oral) | N | null | 320023373 | NIVOLUMAB |
| 320006620 | 320003990 | 1.76 | null | Palliative (P) | 2015-12-06 | 2015-12-07 | VAC | N | null | 320023380 | CAPECITABINE + OXALIPLATIN |
| 320006621 | 320003991 | null | 78.9 | Palliative (P) | 2013-10-29 | 2013-10-31 | Niraparib | Y | null | 320023393 | CARBOPLATIN + VINCRISTINE |
| 320006622 | 320006708 | 1.71 | 48.2 | Palliative (P) | 2015-10-19 | 2015-11-10 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 320023433 | CAPECITABINE + TEMOZOLOMIDE |
| 320006623 | 320005835 | 1.54 | 82.8 | Curative (C) | 2015-06-24 | 2017-01-20 | CISPLATIN + ETOPOSIDE | N | N | 320023477 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320006624 | 320003998 | 1.48 | 51.5 | Curative (C) | 2016-05-08 | 2016-10-01 | Carboplatin + Cetux + FU (>Cycle 2) | N | N | 320023507 | ICON8B TRIAL |
| 320006626 | 320004004 | 1.69 | 72.4 | Palliative (P) | 2018-02-10 | 2018-03-03 | CARBOPLATIN + ETOPOSIDE | Y | 2 | 320023538 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320006627 | 320006709 | 1.76 | null | Adjuvant (A) | 2017-11-22 | 2017-12-24 | Etoposide oral | N | null | 320023546 | DOCETAXEL |
| 320006628 | 320004008 | 1.8 | 112.8 | Palliative (P) | 2015-04-18 | 2015-04-19 | Capecitabine (21days) + Carboplatin | 01 | N | 320023562 | CARBO + FLUOROURACIL |
| 320006629 | 320004009 | null | 69.8 | Neo-adjuvant (N) | 2015-07-25 | 2015-07-25 | Bevacizumab+Carbo+Pacliaxel | Y | N | 320023577 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320006630 | 320004011 | 1.58 | 64.7 | Palliative (P) | 2018-04-03 | 2018-04-06 | GEMCITABINE | 02 | N | 320023597 | CISPLATIN + GEMCITABINE |
| 320006631 | 320004014 | 1.67 | 54.1 | Palliative (P) | null | 2014-05-03 | POUT TRIAL | N | N | 320023661 | ICON TRIAL |
| 320006632 | 320004015 | 1.76 | 0 | Palliative (P) | 2017-05-15 | 2017-05-20 | Cetuximab+Cisplatin+FU (> Cycle 2) | 02 | N | 320023678 | TEMOZOLOMIDE |
| 320006633 | 320004016 | 1.78 | 77.9 | Curative (C) | 2014-05-10 | 2014-05-18 | Fluorouracil 96hr infusion+R(4g/m2) | 02 | N | 320023680 | ENZALUTAMIDE |
| 320006635 | 320004020 | 1.76 | 87.5 | Curative (C) | 2015-08-31 | 2015-09-04 | CAPECITABINE + IRINOTECAN | 2 | N | 320023682 | VEMURAFENIB |
| 320006636 | 320004024 | 1.78 | 81.1 | Palliative (P) | 2017-06-03 | 2017-08-08 | CARBOPLATIN + VINORELBINE | 2 | N | 320023697 | CETUXIMAB + CISPLATIN + FU |
| 320006637 | 320004027 | 1.76 | 71.4 | Palliative (P) | 2015-01-10 | 2015-01-28 | CARBOPLATIN + CETUXIMAB + FU | Y | N | 320023706 | CARBOPLATIN + CETUXIMAB + FU |
| 320006638 | 320005847 | null | 94.2 | Palliative (P) | 2017-07-28 | 2017-08-22 | PEMBROLIZUMAB | N | N | 320023709 | CETUXIMAB + RT |
| 320006639 | 320004032 | null | 82.8 | Palliative (P) | 2016-07-21 | 2016-07-25 | ICON8B TRIAL | 2 | N | 320023757 | NAB-PACLITAXEL |
| 320006640 | 320005849 | null | 64.2 | null | 2015-02-19 | 2015-02-19 | Cyclophosphamide PO +Vinorelbine IV | 02 | N | 320023794 | DOXORUBICIN |
| 320006641 | 320004038 | 1.8 | 97 | Palliative (P) | 2016-09-09 | 2016-11-29 | POUT TRIAL | N | N | 320023826 | CARBOPLATIN + RT |
| 320006642 | 320005851 | 1.79 | 91.5 | Palliative (P) | 2018-05-12 | 2018-05-14 | PEMBROLIZUMAB | 01 | N | 320023838 | CARBOPLATIN + DOCETAXEL |
| 320006643 | 320004043 | 1.72 | 83.9 | Palliative (P) | 2018-04-23 | 2018-04-24 | Docetaxel | 02 | N | 320023860 | IBRUTINIB |
| 320006644 | 320006713 | 1.7 | 62.4 | Neo-adjuvant (N) | 2017-12-26 | 2017-12-30 | CETUXIMAB + RT | N | Y | 320023912 | GEMCITABINE |
| 320006645 | 320004052 | 1.56 | 87.85 | Adjuvant (A) | 2015-09-14 | 2017-03-03 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | N | N | 320023924 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 320006646 | 320004056 | 1.53 | 96.4 | Palliative (P) | null | 2015-01-01 | IVA | null | null | 320023942 | CAPECITABINE |
| 320006647 | 320005858 | null | 95.5 | Palliative (P) | 2017-01-09 | 2017-01-20 | CARBOPLATIN + RT | 2 | N | 320023958 | CARBO + FLUOROURACIL |
| 320006648 | 320004060 | null | 60.4 | Adjuvant (A) | 2017-11-06 | 2017-12-21 | Temozolomide 150mg/m2 | N | N | 320023983 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320006649 | 320004061 | 1.83 | 78 | Palliative (P) | 2014-12-11 | 2014-12-11 | Bevacizumab + CAPECITABINE + OXALIPLATIN | N | N | 320023993 | CARBOPLATIN + RT |
| 320006650 | 320004063 | null | 61 | Palliative (P) | 2016-06-03 | 2016-06-03 | PEMBROLIZUMAB | 2 | N | 320023997 | CVD |
| 320006651 | 320004064 | 1.8 | 62.2 | Palliative (P) | 2017-03-17 | 2017-08-22 | Carboplatin + Cetux + FU (Cycle 1) | 02 | N | 320024003 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320006652 | 320004067 | 1.85 | 94 | Disease modification (D) | 2014-06-01 | 2014-06-01 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | N | 320024026 | TCF |
| 320006653 | 320004069 | 1.69 | null | Palliative (P) | 2013-09-28 | 2013-11-30 | ICON8B TRIAL | N | N | 320024027 | CARBOPLATIN + ETOPOSIDE |
| 320006655 | 320004074 | 1.71 | 60 | Neo-adjuvant (N) | 2014-02-23 | 2014-05-01 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 320024034 | NIRAPARIB |
| 320006656 | 320004076 | 1.66 | 62 | Palliative (P) | 2017-05-28 | 2017-09-30 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 320024052 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320006657 | 320004078 | 1.65 | 55.8 | Palliative (P) | null | 2019-08-03 | Olaparib | N | N | 320024060 | ECX |
| 320006658 | 320004079 | null | 63.7 | Palliative (P) | 2017-01-29 | 2017-02-28 | POUT TRIAL | N | N | 320024075 | PEMETREXED |
| 320006659 | 320005870 | 1.59 | null | Palliative (P) | 2014-07-09 | 2014-07-15 | POUT TRIAL | N | null | 320024083 | POMALIDOMIDE |
| 320006660 | 320004082 | 1.64 | 54.6 | Palliative (P) | 2016-08-19 | 2016-10-12 | Cisplatin + Vinorelbine (IV) | N | N | 320024088 | PCV |
| 320006661 | 320004085 | 1.71 | 65 | Palliative (P) | 2017-03-02 | 2017-03-26 | Trabectedin | N | N | 320024091 | CETUXIMAB + CISPLATIN + FU |